Back to Search
GARY HILLMAN, D.O.
D.O.
Emergency Medicine Physician
NPI: 1760444160IndividualAccepts Medicare
Specialties, Licenses & Credentials
Emergency Medicine PhysicianPrimary
Emergency Medicine
Code: 207P00000X
3957(OK)
CMS Specialties
PrimaryEMERGENCY MEDICINE
Education
OTHER
Class of 1998
Research & Publications (20)
The property distance index PD predicts peptides that cross-react with IgE antibodies.
PMID 18950868·Mol Immunol·2009
8-other
DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping.
PMID 19169185·CNS Spectr·2009
4-observational
Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells.
PMID 19101986·Int J Cancer·2009
8-other
Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model.
PMID 17304503·Int J Cancer·2007
7-preclinical
Progression of renal cell carcinoma is inhibited by genistein and radiation in an orthotopic model.
PMID 17212824·BMC Cancer·2007
7-preclinical
Radiosensitization of prostate cancer by soy isoflavones.
PMID 18220535·Curr Cancer Drug Targets·2007
6-review
Serotonin2C receptor localization in GABA neurons of the rat medial prefrontal cortex: implications for understanding the neurobiology of addiction.
PMID 17467185·Neuroscience·2007
7-preclinical
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
PMID 16815318·Clin Pharmacol Ther·2006
8-other
Prostate cancer treatment is enhanced by genistein in vitro and in vivo in a syngeneic orthotopic tumor model.
PMID 16808622·Radiat Res·2006
7-preclinical
Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest.
PMID 16640785·BMC Cancer·2006
8-other
Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer.
PMID 16307003·Gene Ther·2006
7-preclinical
Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein.
PMID 15761259·Hum Gene Ther·2005
7-preclinical
Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model.
PMID 15486194·Mol Cancer Ther·2004
7-preclinical
Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
PMID 16219165·Cell Mol Immunol·2004
6-review
Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules.
PMID 15195928·Curr Opin Mol Ther·2004
7-preclinical
Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.
PMID 15059651·Cancer Treat Rev·2004
4-observational
Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma.
PMID 14681727·Cancer Gene Ther·2004
7-preclinical
Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase.
PMID 14669797·Clin Exp Metastasis·2003
7-preclinical
Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells.
PMID 12900767·Gene Ther·2003
7-preclinical
Responsiveness of experimental prostate carcinoma bone tumors to neutron or photon radiation combined with cytokine therapy.
PMID 12873689·Int J Radiat Oncol Biol Phys·2003
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4050 W MEMORIAL RD, ER DEPT
OKLAHOMA CITY, OK 73120 - Phone
- (405) 608-3402
Quick Facts
- NPI
- 1760444160
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 28
- Publications
- 20
Are you this provider?
Claim Your Profile